FREESIA-3 Study Adds First US Site The study is recruiting up to 50 participants to assess the efficacy and safety of nipocalimab in reducing the risk of severe FNAIT.

Philadelphia @pennmedicine.bsky.social has been added as a site for the #FREESIA3 trial investigating #Nipocalimab vs intravenous immunoglobulin (#IVIG) in pregnancies at risk of fetal and neonatal alloimmune thrombocytopenia (#FNAIT).

Read more: https://bit.ly/4mZjRhb

#RareSky #MedSky